Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Fractyl Health, Inc. ( (GUTS) ) has shared an announcement.
On March 24, 2026, Fractyl Health reported fourth-quarter and full-year 2025 results and detailed progress in its Revita clinical program for post-GLP-1 weight maintenance, including completion of randomization in the REMAIN-1 Pivotal Cohort and new post-hoc analyses from the Midpoint Cohort. These analyses showed a statistically significant, dose-dependent relationship between duodenal ablation length and weight maintenance, with patients who had greater prior GLP-1-induced weight loss and longer ablations experiencing substantially less weight regain than sham controls.
Prior clinical data from a Germany real-world registry and the REVEAL-1 and REMAIN-1 Midpoint cohorts in 2025 and early 2026 showed durable weight loss, improved glycemic control, and around 70% less post-GLP-1 weight regain versus sham, bolstering confidence in the pivotal trial design. Fractyl also disclosed favorable FDA feedback suggesting its Revita DMR system safety profile is consistent with Class II classification and outlined 2026 milestones, while reaffirming a cash runway into early 2027 and highlighting progress in its Rejuva gene therapy pipeline, including CTA submissions and planned first-in-human dosing of RJVA-001.
The company updated its corporate and REMAIN-1 Midpoint Cohort presentations for investors on March 24, 2026 to incorporate the new post-hoc analyses linking procedural dose and prior GLP-1 weight loss to Revita’s treatment effect. This operational, clinical, and regulatory momentum positions Fractyl as a potential first mover in procedural solutions for post-GLP-1 weight maintenance, with key data readouts and a potential De Novo submission targeted for late 2026, which could materially influence its standing in the obesity and diabetes treatment landscape.
The most recent analyst rating on (GUTS) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Fractyl Health, Inc. stock, see the GUTS Stock Forecast page.
Spark’s Take on GUTS Stock
According to Spark, TipRanks’ AI Analyst, GUTS is a Neutral.
The score is held down primarily by very weak financial performance (minimal/declining revenue, large ongoing losses, heavy cash burn, and slightly negative equity). Technicals also lean bearish (below short-term moving averages with weak RSI/MACD). Offsetting these, earnings-call commentary was relatively positive due to encouraging clinical results, strong cash position/runway into early 2027, and clear 2026 milestones, but it is not enough to overcome current financial and momentum risks.
To see Spark’s full report on GUTS stock, click here.
More about Fractyl Health, Inc.
Fractyl Health, Inc. is a clinical-stage metabolic therapeutics company developing novel treatments for obesity and type 2 diabetes, with a focus on procedural and gene therapy approaches. Its lead procedural therapy, Revita, targets the duodenal mucosa to help maintain weight loss after GLP-1 drug discontinuation, while its Rejuva platform advances gene therapies aimed at long-term metabolic disease remission.
Average Trading Volume: 5,551,997
Technical Sentiment Signal: Sell
Current Market Cap: $61.11M
For detailed information about GUTS stock, go to TipRanks’ Stock Analysis page.